CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net income	$ 1,398.9	$ 1,075.1
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	58.5	57.8
Amortization	192.1	131.3
Deferred income taxes	(166.7)	(252.6)
Impairment charges	132.6	5.6
Change in value of contingent consideration	(10.7)	(10.3)
Gain on sale of business	(37.5)	0.0
Net (gain) loss on sale of investments	(7.1)	(85.6)
Share-based compensation expense	304.0	276.5
Share-based employee benefit plan expense	19.7	17.1
Derivative instruments	(14.3)	(4.0)
Other, net	1.5	(3.8)
Change in current assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	(80.7)	(140.9)
Inventory	(45.2)	(19.2)
Other operating assets	100.4	(46.8)
Accounts payable and other operating liabilities	55.0	76.8
Income tax payable	13.6	32.8
Deferred revenue	(3.2)	31.1
Net cash provided by operating activities	1,910.9	1,140.9
Cash flows from investing activities:
Proceeds from sales of marketable securities available for sale	428.0	1,579.8
Purchases of marketable securities available for sale	(432.0)	(1,127.1)
Capital expenditures	(103.3)	(95.0)
Proceeds from sales of investment securities	11.3	85.2
Purchases of investment securities	(89.6)	(200.2)
Other	0.0	(3.0)
Net cash (used in) provided by investing activities	(185.6)	239.7
Cash flows from financing activities:
Payment for treasury shares	(1,706.3)	(1,997.3)
Proceeds from short-term borrowing	0.0	970.9
Principal repayments on short-term borrowing	0.0	(209.7)
Net proceeds from common equity put options	5.8	6.4
Net proceeds from share-based compensation arrangements	75.9	104.2
Excess tax benefit from share-based compensation arrangements	82.1	174.2
Net cash used in financing activities	(1,542.5)	(951.3)
Effect of currency rate changes on cash and cash equivalents	0.6	(20.1)
Net increase in cash and cash equivalents	183.4	409.2
Cash and cash equivalents at beginning of period	4,880.3	4,121.6
Cash and cash equivalents at end of period	5,063.7	4,530.8
Supplemental schedule of non-cash investing and financing activity:
Change in net unrealized loss on marketable securities available for sale	353.3	8.3
Investment in Human Longevity, Inc. common stock	39.6	0.0
Supplemental disclosure of cash flow information:
Interest paid	264.8	120.2
Income taxes paid	$ 227.1	$ 247.2